


Journal Pre-proof

Comparative proteomic analysis reveals functional and evolutionary diversity in five *Montivipera* snake venoms

Christina Sahyoun, Damien Redureau, Thomas Crasset, Rudy Fourmy, Aude Violette, Vincent Leignel, Ziad Fajloun, César Mattei, Christian Legros, Loïc Quinton



PII: S0041-0101(26)00035-8

DOI: <https://doi.org/10.1016/j.toxicon.2026.109017>

Reference: TOXCON 109017

To appear in: *Toxicon*

Received Date: 8 December 2025




Revised Date: 20 January 2026

Accepted Date: 27 January 2026

Please cite this article as: Sahyoun, C., Redureau, D., Crasset, T., Fourmy, R., Violette, A., Leignel, V., Fajloun, Z., Mattei, C., Legros, C., Quinton, L., Comparative proteomic analysis reveals functional and evolutionary diversity in five *Montivipera* snake venoms, *Toxicon*, <https://doi.org/10.1016/j.toxicon.2026.109017>.

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2026 Published by Elsevier Ltd.



1 **Comparative proteomic analysis reveals functional and evolutionary diversity in**
2 **five *Montivipera* snake venoms**

3 Christina Sahyoun^{1,2}, Damien Redureau³, Thomas Crasset³, Rudy Fourmy⁴, Aude
4 Violette⁴, Vincent Leignel⁵, Ziad Fajloun^{2,6}, César Mattei^{1*}, Christian Legros^{1*}, Loïc
5 Quinton^{3*}

6 ¹Univ. Angers, INSERM, CNRS, MITOVASC, Equipe CarME, SFR ICAT, 49000 Angers,
7 France.

8 ²Laboratory of Applied Biotechnology (LBA3B), Department of Cell Culture, Azm Center
9 for Research in Biotechnology and Its Applications, EDST, Lebanese University, Tripoli
10 1300, Lebanon.

11 ³Laboratory of Mass Spectrometry, MolSys Research Unit, University of Liège, 4000
12 Liège, Belgium.

13 ⁴Alphabiotoxine Laboratory srl, Barberie 15, 7911 Montroeuil-au-bois, Belgium.

14 ⁵Laboratoire BiOSSE, Le Mans Université, Avenue Olivier Messiaen, 72085 Le Mans,
15 France

16 ⁶Department of Biology, Faculty of Sciences III, Campus Michel Slayman Ras Maska,
17 Lebanese University, Tripoli 1352, Lebanon

18

19 Corresponding authors: loic.quinton@uliege.be; cesar.mattei@univ-angers.fr;
20 christian.legros@univ-angers.fr

21

22

23

24 **Abstract**

25 Proteomic characterization of snake venoms is essential for understanding the molecular
26 basis of their evolution and for identifying bioactive compounds of therapeutic interest.
27 The *Montivipera* species endemic to the Near and Middle East region remain poorly
28 studied despite their interesting biological activities. Previous analyses of *Montivipera*
29 venoms have provided only partial proteomic profiles, with notable discrepancies between
30 studies. To address this gap, we conducted a proteomic analysis of five *Montivipera*
31 species, including *M. bornmuelleri*, *M. bulgardaghica*, *M. albizona*, *M. raddei* and *M.*
32 *xanthina*. We also analyzed the venom of *Macrovipera lebetina* ssp. to provide a broader
33 comparative framework. These venoms were investigated using an integrated approach
34 combining SDS-PAGE, RP-HPLC and shotgun proteomics, using both trypsin and multi-
35 enzymatic limited digestions to maximize protein identification and coverage. SDS-PAGE
36 and RP-HPLC analyses revealed the remarkable complexity and diversity of *Montivipera*
37 venoms, which were further confirmed by shotgun proteomics, identifying between 129
38 and 179 proteins and peptides per species. The major protein families detected included
39 snake venom metalloproteinases, phospholipases A₂, venom serine proteases, C-type
40 lectins, venom vascular-endothelial growth factors, and disintegrins. Notably, the relative
41 abundance of these protein families varied across species, suggesting interspecific
42 differences in envenomation profiles. Comparative analysis revealed a high degree of
43 similarity among *Montivipera* species, with 39 shared proteins across all five venoms. Our
44 findings confirmed the major toxin families previously reported in *Montivipera* venoms and
45 revealed the presence of several low-abundance protein families that were not previously
46 identified. Thus, this study highlights both the conserved and unique features of

- 47 *Montivipera* venom proteomes, offering a valuable foundation for future functional and
48 evolutionary investigations.

Journal Pre-proof


49 1 Introduction

50 Snake venom (SV) serves as a potent chemical weapon, enabling snakes to subdue their
51 prey or to defend against predators and humans. These venoms are complex cocktails
52 containing hundreds of biologically active proteins and peptides that selectively target
53 vital organs [1]. The molecular composition of SV varies at different taxonomic levels,
54 defined as interfamilial, intergeneric, interspecific, and intraspecific variability [2]. Such
55 differences have a significant impact on the curative effects of antivenoms, which remain
56 the most effective treatment against snakebite to date [3]. Thus, the determination of SV
57 composition at the species level is essential to develop specific antivenoms, ensuring
58 effective management of snakebites. Additionally, characterizing SV is crucial for the
59 discovery of novel bioactive proteins and peptides with putative therapeutic potential [4].
60 Furthermore, SV proteomic characterization can help understand the evolutionary
61 mechanisms driving venom diversity, adaptation, and speciation [5].

62 The *Montivipera* genus has a relatively recent history of discovery, and according to
63 different authors 8 to 10 species have been described so far [6]. These mountain vipers
64 are endemic to the Near and Middle East region encompassing Türkiye, Armenia,
65 Azerbaijan, Iran, Syria, and Lebanon and are found at altitudes between 1000 and 2000
66 m above sea level (a.s.l.) (IUCN red list, <https://www.iucnredlist.org>) (**Fig. 1**). They can
67 be identified by their distinct colored dorsal patterns and body lengths ranging from 20 to
68 80 cm, in combination with other morphometric characters. The venoms of *Montivipera*
69 *sp.* remain scarcely studied so far. To address this knowledge gap, this study proposes a
70 comprehensive venom investigation from five *Montivipera* species: *M. bornmuelleri*, *M.*
71 *bulgardaghica*, *M. xanthina*, *M. raddei*, and *M. albizona*. For comparative purposes, we

72 also included the venom of the closely related sister genus *Macrovipera*, which belongs
 73 to the Old-World viper clade. Venoms from the genus *Macrovipera* have been well
 74 documented in the literature, particularly with respect to their proteomic composition and
 75 pharmacological activities [7–9]. In the present study, we specifically analyzed the venom
 76 of the *Macrovipera lebetina* ssp., sourced from the same geographical region as the
 77 studied *Montivipera* species.

78



79

80 **Fig. 1** Geographical distribution of *Montivipera* species. *M. bornmuelleri* lives in Lebanese
81 mountains (1000 to 2000 m a.s.l.), *M. xanthina* is found in Türkiye and Greece (0 to 2000
82 m a.s.l.), *M. bulgardaghica* is found in Turkish Taurus mountains (2000 m a.s.l.), *M. raddei*
83 is present in Armenia, Türkiye, Iraq, Iran and Azerbaijan (1000 to 2000 m a.s.l.), *M.*
84 *albizona* is found in the Anatolian diagonal in Türkiye (1500 and 1800 m a.s.l.) (The map
85 was from Google (without copyright) and constructed using Powerpoint 2019 based data
86 from the IUCN red list, <https://www.iucnredlist.org>) – © Snake photographs were used
87 with the permission of the respective photographers.

88

89 Since the *Montivipera* species inhabits high altitudes –hence their name “Mountain-viper
90 – human snakebites are rare. The recorded clinical manifestations upon *Montivipera*
91 envenomation include local symptoms such as swelling, ecchymosis, tissue damage and
92 local haemorrhage, while systemic symptoms include hemostatic alterations,
93 neurotoxicity and hypotension [10–12]. Importantly, it has been shown that in the absence
94 or delay of antivenom administration, a *Montivipera* snakebite can lead to long-term
95 morbidity or even mortality [11,13]. Up till now, no antivenoms are available for
96 *Montivipera* species except for a polyvalent antivenom developed against *M. xanthina*
97 among other Eurasian vipers [14]. Therefore, a deep proteomic characterization of
98 *Montivipera* venoms can allow the exploration of the potential cross-reactivity of existing
99 antivenoms, which is particularly relevant given the limited clinical need and lack of
100 commercial interest in developing species-specific antivenoms.

101 At the functional level, the *Montivipera* venoms are poorly studied. However, a few
102 investigations of their biological activities have shown promising biomedical potential.

103 Specifically, the venoms of *M. raddei* and *M. bulgardaghica* exhibit cytotoxic effects on
104 both cancerous and non-cancerous cell lines, suggesting potential anti-proliferative
105 properties [15]. In addition, *M. xanthina* venom has both cytotoxic and antimicrobial
106 effects on cancer cell lines and on fungi and bacteria, respectively [16,17]. Moreover, *M.*
107 *bornmuelleri* venom has been the most studied, revealing a range of interesting biological
108 activities, including antimicrobial, pro- and anticoagulant, cytotoxic, immunomodulatory,
109 neurotoxic, and vasorelaxant effects [18–24]. These activities evidence the diversity of
110 *Montivipera* venom components, underscoring the importance of their identification and
111 characterization for both therapeutic development and research applications.

112 The venom proteomic content of four *Montivipera* species, including *M. xanthina*, *M.*
113 *bulgardaghica*, *M. raddei* and *M. albizona*, has recently been evaluated. These studies
114 show that the main protein families constituting these *Montivipera* venoms are venom
115 metalloproteinases, venom serine proteases, phospholipase A₂, C-type lectins and
116 venom vascular endothelial growth factor [15,25–27]. These studies yielded variable
117 results regarding both the number of proteins identified in each venom and the different
118 low abundance protein families detected. Thus, the characterization of the proteomic
119 composition of these four venoms remains to be performed to validate and complete
120 previous reports. Moreover, the composition of *M. bornmuelleri* venom has never been
121 analyzed and still represents an important knowledge gap.

122 SV proteomes can be analyzed through different workflows, each having its advantages
123 and disadvantages [28,29]. Shotgun proteomics is however the current gold standard for
124 venom proteome deciphering as it offers a comprehensive, high-throughput approach to
125 venom analysis, enabling the simultaneous identification (and relative quantification) of a

126 broad range of proteins without the need for prior toxin separation. Unlike traditional gel-
127 based or targeted methods, it allows for deeper coverage of low-abundance components
128 and post-translational modifications, which are critical for understanding venom
129 complexity. This makes it particularly well-suited for profiling poorly characterized
130 venoms, such as those of *Montivipera* species. The current work, additionally to shotgun
131 proteomics, proposes to combine the classical trypsin digestion with the more recent
132 Multi-Enzymatic Limited Digestion (MELD) [30]. Unlike conventional approaches, MELD
133 minimizes sample loss and biases toward abundant proteins, enabling more accurate
134 identification of low-abundance venom components. By generating a higher number of
135 overlapping peptides for each toxin, it improves the protein sequence coverage and leads
136 to more confident assignment of venom toxins. The integration of both trypsin and MELD
137 digestion for analyzing SVs has been recently demonstrated to be effective for obtaining
138 a comprehensive SV composition [31,32].

139 Therefore, this study aims to analyze the venom composition of the five previously
140 mentioned *Montivipera* venoms by employing SDS-PAGE, RP-HPLC and shotgun
141 proteomics using Trypsin and MELD digestions. This allows us to determine the
142 proteomic composition of *M. bornmuelleri* for the first time, in addition to complementing
143 and validating the previously published venom proteomes of *M. bulgardaghica*, *M.*
144 *albizona*, *M. raddei* and *M. xanthina*. Besides uncovering the proteomic profiles of the
145 *Montivipera* venoms, we aimed to perform a comparative analysis of their proteomes to
146 provide information about venom evolution among species of the *Montivipera* genus that
147 live in non-overlapping geographical habitats. For comparison purposes, the *Macrovipera*

148 *lebetina* ssp. venom was analyzed as an outgroup, providing a phylogenetic reference
149 point that helps distinguish lineage-specific traits among *Montivipera* venoms.

150

151 **2 Materials and Methods**

152

153 **2.1 Reagents and chemicals**

154 Coomassie Brilliant Blue (CBB) R250 (C.I 42660, Sigma-Aldrich Merck), Acetonitrile
155 (ACN, 412412000-CER, Carlo Erba), Ultrapure water (412142-CER, Carlo Erba),
156 Trifluoroacetic acid (TFA, 152005, Sigma Aldrich Merck), dithiothreitol ultrapure molecular
157 biology grade (DTT, Thermo scientific), iodoacetamide bio-ultra pure (IAA, Sigma aldrich),
158 Trypsin (Thermo scientific, MS grade), Chymotrypsin (Thermo scientific, MS grade), Glu-
159 C (Thermo scientific, MS grade), formic acid (FA, Biosolve, ULC-MS/GC-SFC 99%).

160 **2.2 Venoms**

161 Venom samples of *M. bornmuelleri* were purchased from Latoxan (Portes-lès-Valence,
162 France). The venoms of *M. bulgardaghica*, *M. raddei*, *M. albizona*, *M. xanthina* and
163 *Macrovipera lebetina* were purchased from Alphabiotoxine (Montroeuil-au-bois, Belgium).
164 *Macrovipera lebetina* venom samples used in this study were obtained from specimens
165 sourced from Mersin, southern Anatolia, Turkey, and are hereafter referred to
166 as *Macrovipera lebetina* ssp., reflecting geographic origin without implying a definitive
167 subspecies assignment. Venoms were sourced from animals bred and kept in captivity.
168 Animals originated from different geographical locations as follows: *M. bornmuelleri*
169 (Lebanon), *M. bulgardaghica* (Türkiye), *M. raddei* (Türkiye), *M. xanthina* (Türkiye), *M.*
170 *albizona* (Türkiye) and *Macrovipera lebetina* ssp. (Türkiye).

171

172

173 **2.3 SDS-PAGE analysis**

174 *Montivipera* venom samples were separated using 12% polyacrylamide gels in the
175 presence of SDS (SDS-PAGE). For this, 10 µg of the venom samples were mixed with
176 Laemmli 5x buffer under reducing conditions (12.5% β-mercaptoethanol) or non-reducing
177 conditions [33]. Samples were then heated at 95°C for 5 min and loaded onto the gel. The
178 Precision Plus Protein Standard Kaleidoscope™ protein ladder was used as a molecular
179 weight (MW) marker. Protein bands were visualized by CBB R250 staining for 1h at RT.
180 Gel images were captured using the Chemidoc™ XRS+ imaging system. A linear
181 regression logarithmic plot of molecular mass versus relative migration distance served
182 as a calibration curve to calculate the MW, corresponding to each band.

183

184 **2.4 Chromatographic Profiling**

185 Lyophilized *Montivipera* venoms were dissolved in ACN/H₂O (5:95, v/v) at concentrations
186 of 0.5 mg/mL. Venom samples (100 µg) were centrifuged at 10,000 xg for 10 minutes at
187 4°C to eliminate impurities. The supernatants were applied onto a C18 Vydac® column
188 218TP54 (250 x 4.6mm, 5 µm, 300 Å) for fractionation. The chromatographic run was
189 performed on a Waters HPLC system coupled to a Waters 600 controller and a Waters
190 2487 dual wavelength UV detector. Venoms were eluted using a segmented three-step
191 gradient of solvent B in solvent A, going from 5 to 30% B in 8 min, 30 to 75% B in 27 min
192 and 75 to 100% B in 5 min. The total run duration was 40 min at a flow rate of 1 mL/min.
193 Solvent B consisted of 0.1% TFA in ACN, and solvent A was composed of 0.1% TFA in

194 ultrapure water. The UV-absorbance of the eluted venom components was monitored at
195 214 and 280 nm. The data acquisition was performed using Waters Empower 3 software.
196 Peak integration was performed automatically by Empower 3 software and manually
197 adjusted when necessary.

198

199 **2.5 Proteomics analysis**

200 **2.5.1 Sample preparation**

201 Lyophilized venoms (10 µg) were dissolved in 2 µL of 50 mM NH_4HCO_3 at pH 7.8.
202 Reduction of the venom protein and peptide disulfides was performed using 2 µL of 30
203 mM DTT for 40 min at 56°C while shaking at 650 rpm. The reduced cysteines were then
204 alkylated using 3 µL of 60 mM IAA for 30 min at RT at dark. A quench of the alkylation
205 reaction was performed by incubating the samples in 11 mM DTT for 10 min at RT in the
206 dark. For the digestion of the samples, two different protocols were employed: the
207 conventional trypsin digestion and the MELD, where 3 proteolytic enzymes are used
208 simultaneously to digest the venom samples, including trypsin, chymotrypsin, and Glu-C.

209 ***Trypsin digestion.*** A first trypsin digestion was performed by adding proteomic grade
210 enzyme to the reduced and alkylated venom samples to reach a final trypsin/substrate
211 ratio of 1/50. Samples were then incubated overnight at 37°C, while shaking at 650 rpm.
212 A second tryptic digestion was performed the following day to a trypsin/substrate ratio of
213 1/100 in ACN at a final concentration of 80% (v/v) for 3h at 37°C. The enzymatic digestion
214 was quenched by acidification of the medium using TFA at a final concentration of 0.5%,
215 to reach pH 3.0. The digested samples were speed-dried and reconstituted in 20 µL of

216 0.1% TFA for desalting on ZipTip[®] C18 resin pipette tips Pierce[™] according to the
217 manufacturer's protocol. The elution was performed using 20 μ L of 50.0% ACN, 49.9%
218 H₂O, 0.1% TFA (v/v). The resulting eluates were lyophilized and reconstituted to 15
219 pmol/9 μ L in H₂O containing 0.1% TFA, then submitted to mass spectrometry analysis.

220 **MELD digestion.** The multi-enzymatic limited digestion involved two parallel digestions
221 of 10 μ g of lyophilized venoms with the same enzymes but at different ratios. A MELD
222 concentrated digestion was performed at enzyme/substrate ratios of 1/85, 1/85, and 1/55
223 for trypsin, Glu-C, and chymotrypsin, respectively. Simultaneously, a MELD diluted
224 digestion was performed at enzyme/substrate ratios of 1/750, 1/750, and 1/500 for trypsin,
225 Glu-C, and chymotrypsin, respectively. Enzyme mixtures were prepared on ice in 25 mM
226 NH₄HCO₃ and 5 mM CaCl₂ solution. Digestions were performed at 37°C for 2 h while
227 shaking at 650 rpm. The reactions were stopped using TFA at a final concentration of
228 0.5%. Both concentrated and diluted MELD digests were pooled, and 3.5 μ g of venom-
229 digested samples were desalted using ZipTip[®] C18 resin pipette tips Pierce[™] according
230 to the manufacturer's protocol. The resulting digests were lyophilized and reconstituted
231 to 15 pmol/9 μ L in H₂O with 0.1% TFA for mass spectrometry analysis.

232

233 **2.5.2 Mass spectrometry analysis**

234 Digested samples were analyzed using an Acquity M-class ultra-high-performance liquid
235 chromatography (UPLC) system (Waters, Corp., Milford, CT, USA) coupled with a Q-
236 Exactive mass spectrometer (Thermo Scientific, Waltham, MA, USA) in nano-
237 electrospray positive ion mode. The trap column used ahead of the analytical column was
238 a Symmetry C18 5 μ m (180 μ m x 20 mm). Venom digests separation was performed using

239 an analytical HSS T3 C18 1.8 μm (75 μm x 250 μm) (Waters, Corp., Milford, CT, USA)
240 chromatographic column. Samples were loaded at 20 $\mu\text{L}/\text{min}$ on the trap column in 98%
241 solvent A and 2% solvent B for 3 min and were subsequently separated on the analytical
242 column at a flow rate of 500 nL/min using a linear gradient as follows: initial condition 2%
243 solvent B hold for 2 min; 2 to 7% B in 5 min; 7 to 30% B in 55 min; 30 to 40% B in 10 min;
244 40 to 90% B in 3 min; maintained at 90% for 5 min before the column was reconditioned
245 to initial conditions. The mobile phase composition was as follows: solvent A was made
246 of 0.1% FA in water and solvent B was made of 0.1% FA in ACN.

247 The nano-HPLC was connected to a Q-Exactive Hybrid Quadrupole-Orbitrap mass
248 spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The mass spectrometer
249 method is a TopN-MSMS method where N was set to 12, meaning that the spectrometer
250 acquires one Full MS spectrum, selects the 12 most intense peaks in this spectrum (singly
251 charged and unassigned charge precursors excluded) and makes a Full MS² spectrum
252 of each of these 12 compounds. Precursor mass was measured by an Orbitrap mass
253 analyzer at the resolution of 70,000 (at m/z 200) and a mass range of 400 to 1600 m/z.
254 AGC target of 3×10^6 or maximum injection time of 200 ms. Data was collected in data-
255 dependent acquisition (DDA) mode. For MS² analysis, the 12 most intense precursor ions
256 were selected for high-energy collision-induced dissociation with an isolation window of
257 2.0 m/z. The fragmented ions were scanned at a resolution of 17,500 (at m/z 200) with
258 an AGC target of 1×10^5 or maximum injection time of 50 ms. Normalized collision energy
259 (NCE) set at 27. The main parameters for Q-Exactive tune were spray voltage of 2.3 kV,
260 capillary temperature of 270°C and S-Lens RF level of 50.0.

261 Protein identification by automated *de novo* sequencing was performed using the
262 software Peaks Studio X+ version 10.5 against the database created by the deposits
263 related to “Snake + venom” in the UniProt repository (117,665 sequences, April 2024).
264 Carbamidomethylation was set as a fixed modification, and oxidation (M) and
265 Deamidation (NQ) were set as variable modifications, with a maximum missed cleavage
266 number limited to 2. Precursor mass and fragment mass error tolerances were set at 5
267 ppm and 0.015 Da, respectively. A false discovery rate (FDR) of 0.1% and unique peptide
268 ≥ 2 with significant peptides were used to filter out inaccurate proteins for the PEAKS
269 search algorithms and “*De novo* only” analysis with a $-10\lg P > 20$ for the database match
270 with high confidence. To achieve confident results, at least one unique peptide is needed
271 for a protein group. The top proteins were used for classification; these proteins are the
272 components supported by the most unique peptides in the group. The mass spectrometry
273 proteomics data have been deposited to the ProteomeXchange Consortium via the
274 PRIDE [34] partner repository with the dataset identifier PXD073119 and DOI:
275 10.6019/PXD073119.

276

277 **2.5.3 Relative abundance**

278 To estimate the relative abundance of venom proteins, we employed a label-free
279 quantification approach based on the intensity of the three most intense peptide ions
280 detected by mass spectrometry. This method relies on the assumption that the most
281 abundant peptides in each protein contribute significantly to its overall signal intensity. By
282 summing up the intensities of the three most intense ions corresponding to each protein,

283 we obtained a semi-quantitative measure of protein abundance, allowing for comparative
284 analysis of venom composition across samples.

285

286 **2.6 Protein Similarity Coefficient score**

287 To estimate the similarity of venom composition between *Montivipera* species, we used
288 the Protein Similarity Coefficient (PSC) as described by Calvete et al. [35]. We calculated
289 the PSC for two given species, “a” and “b”, using the following formula:

$$290 \quad PSC_{ab} = 2 \times \frac{\text{nb. of proteins shared between a and b}}{\text{total nb. of distinct prot. in a} + \text{total nb. of distinct prot. in b}} \times 100$$

291 Since protein identification was based on sequence homology, we considered two
292 proteins to be similar between venoms if they matched the same reference protein,
293 indicated by an identical accession number. It is important to note that these measures
294 provide only minimal estimates of similarity between the venom profiles. It is likely that
295 some proteins we currently consider identical may, in fact, differ in one or more aspects if
296 complete sequences were available.

297

298 **2.7 Phylogeny**

299 Mitochondrial cytochrome b (cytb) sequences were retrieved from the NCBI Nucleotide
300 database (<https://www.ncbi.nlm.nih.gov/nucleotide>). These sequences were originally
301 published in three independent studies [6,36,37]. Mitochondrial Cytb (88 sequences,
302 1062 bp) was aligned using the MAFFT algorithm with default parameters

303 (<http://mafft.cbrc.jp/alignment/server/> accessed May 1-10, 2025). The best evolutionary
304 model was determined using MEGA X (<https://www.megasoftware.net/> accessed May 1-
305 10, 2025) [38,39]. The maximum likelihood (ML) method and Bayesian inference (BI)
306 procedure were performed using PHYML [40] and MrBayes [41], respectively, available
307 on the NGPHYLOGENY website (<https://ngphylogeny.fr>). Codon positions included were
308 as follows: 1st+2nd+3rd+Non-coding. The final dataset comprised a total of 1,062
309 positions. Bayesian inference analysis was performed for 750,000 generations, 50% of
310 which were eliminated as burn-in. For the maximum likelihood method, the reversible
311 General Time model (BIC: 9460.207, AICc: 7741.886, lnL: -3688.55) and invariant sites
312 ([+I], 67.616% of sites) were applied. The approximate likelihood ratio test (aLRT) was of
313 the SH type. The bootstrapping procedure (number of bootstraps: 1000) and a posterior
314 Probability were applied for ML and BI, respectively. *Macrovipera lebetina* ssp.
315 (KJ415300-301) was used as an outgroup.

316

317 **2.8 Graphs and statistics**

318 Proteomic data was visualized using Microsoft Excel to generate pie charts and bar
319 charts. The Venn diagrams were generated using the multiple list comparator tool from
320 the molecular biology tools (molbiotools) server.

321


322 **3 Results**

323 For clarity and consistency, the following abbreviations for SV components will be used
324 throughout this study: **SVMP**: snake venom metalloproteinase, **PLA₂**: phospholipase A₂,

325 **SVSP**: snake venom serine protease, **svVEGF**: snake venom endothelial growth factor,
326 **CTL**: C-type lectin, **CRISP**: cysteine-rich secretory protein, **SVMPi**: SVMP inhibitor,
327 **LAAO**: L-amino acid oxidase, **AP**: Aminopeptidase, **5'-NT**: 5'-nucleotidase, **PLB**:
328 Phospholipase B, **GC**: Glutaminy cyclase, **PDE**: phosphodiesterase, **NGF**: nerve growth
329 factor, **NP**: natriuretic peptide, **KSPI**: Kunitz-type serine protease inhibitor, **Dis**:
330 Disintegrins

331 **3.1 Phylogenetic analysis**

332 Phylogenetic analysis, ML and BI, involving 88 CYTB mitochondrial sequences from
333 *Montivipera* species, constructed trees with similar typologies confirming the *xanthina*
334 *complex*, including the *xanthina* and *bornmuelleri* clades, and the *raddei* complex
335 established by Stümpel et al. [6]. Phylogenetic tree typology showed a monophyletic
336 clade, “*raddei* complex”, including *Montivipera raddei* (*M. r. raddei*, *M. r. kurdistanica*), *M.*
337 *albicornuta* (with two evolutionary lineages), *M. kuhrangica*, and *M. latifii*. This cluster
338 reflects the geographical proximity of these species, as indicated by Stümpel et al. [6].
339 Another monophyletic clade containing *M. albizona*, *M. bulgardaghica*, *M. wagneri*, and
340 *M. bornmuelleri* is also supported. This clade, named “*bornmuelleri*” by Stümpel et al. [6],
341 is geographically located in the Middle East. Interestingly, individual spec1 named “*M.*
342 *bulgardaghica*” in **Fig. 2** has probably been misidentified as it is grouped with individuals
343 of the *M. albizona* species. In parallel, individuals identified as *Montivipera xanthina*
344 constituted two distinct evolutionary branches independent of geographical origin.
345 Stümpel et al. indicates that lines comprising *M. xanthina* individuals coded xt5, xt6, xt8,
346 and xt9 would reflect a Taurus morphotype [6]. The *xanthina* group seems to originate
347 from the East.




349 **Fig. 2** Evolutionary analyses, based on 88 mitochondrial cytochrome b sequences
350 (CYTB: 1062 bp) from nine species of *Montivipera* (Viperidae, Colubroidea), were carried
351 out using the maximum likelihood method (PhyML) and Bayesian inference (MrBayes).
352 The maximum likelihood tree with the highest likelihood (-3688.55) is shown, and the rate-
353 variation model resulted in some sites being evolutionarily invariant ([+I], 67.62% of sites).
354 Bootstrap values based on 1,000 iterations have been indicated when greater than 50%.
355 A posterior probability is also shown.

356

357 **3.2 SDS-PAGE profile analysis of *Montivipera* venoms**

358 The SDS-PAGE analysis of *Montivipera* venoms revealed that their components belong
359 to a wide range of molecular weights ranging from 9 to ~125 kDa (**Fig. 3**). The banding
360 pattern suggests the presence of protein families commonly found in viperid venoms,
361 including SVMPs, SVSPs, LAAOs, CRiSPs, PLA₂, svVEGFs, CTLs and Dis. The venoms
362 exhibited varying levels of complexity in terms of band number. Under non-reducing
363 conditions, the least diverse venoms displayed 14 bands (*M. bornmuelleri* and *M.*
364 *bulgardaghica*) while the most diverse venom displayed 19 bands (*M. raddei*) (**Fig. 3a**).
365 Notably, the number of bands decreased in reducing conditions highlighting the presence
366 of intermolecular interactions between venom components (**Fig. 3b**). Overall, the
367 migration pattern of *Montivipera* venoms revealed a significant resemblance between
368 venoms with 12 bands being commonly present in all studied *Montivipera* venoms. On
369 the other hand, the venom of the sister genus *Macrovipera lebetina ssp.* revealed major
370 differences in the migration profile compared to the *Montivipera* venoms.



371

372 **Fig. 3** SDS-PAGE profiles of *Montivipera* venoms under **(a)** non-reducing and **(b)**
 373 reducing conditions stained with CBB R250. 1: *M. bornmuelleri*, 2: *M. bulgardaghica*, 3:
 374 *M. xanthina*, 4: *M. raddei*, 5: *M. albizona*, 6: *Macrovipera lebetina* ssp. The red boxes
 375 indicate clusters of protein bands within specific molecular weight ranges, corresponding
 376 to distinct protein families

377


378 3.3 RP-HPLC analysis of *Montivipera* venoms

379 Next, we analyzed the venoms using analytical C18 RP-HPLC. Using our separation
 380 protocol, the *Montivipera* venom profiles displayed between 23 and 33 chromatographic
 381 peaks (**Fig. 4**). The venom chromatograms shared common major chromatographic
 382 peaks notably at retention times of ~10.5, 11.3, 15.7 and 19 min (shaded areas in **Fig.4**).
 383 It is worth noting that these common peaks exhibited different intensities among
 384 *Montivipera* species suggesting that the components within these peaks have different
 385 abundances in the venoms. According to previous proteomic analyses of *Montivipera*

386 venoms, the early-eluting fractions likely contain NPs, KSPI and Disintegrins (shaded in
387 yellow), followed by PLA₂s and SVSPs (shaded in green). The more hydrophobic, late-
388 eluting peaks might be predominantly composed of SVMs and LAAOs (shaded in red)
389 [27,42]. The putative identification of the HPLC peaks composition was inferred from
390 known elution patterns of *Montivipera* venom components. Nevertheless, mass
391 spectrometric characterization is necessary to confirm the precise protein composition of
392 these peaks.

393 Interestingly, certain *Montivipera* venoms exhibited distinct major peaks that were not
394 detected in other venoms, such as the peak eluted at 18.2 min in *M. xanthina* and another
395 at 20.4 min in *M. bulgardaghica* (indicated by red arrows in **Fig.4**). Overall, the RP-HPLC
396 profiles of *Montivipera* venoms showed a high degree of similarity, whereas the profile of
397 *Macrovipera lebetina* ssp. venom appeared more atypical. For instance, the
398 chromatogram of *Macrovipera lebetinus* ssp. did not exhibit the major peaks present in
399 all the *Montivipera* venoms, such as the peaks at retention times 10.5, 15.7 and 19 min
400 (shown in shaded areas).

401



404 **Fig. 4** Chromatographic profiles of *Montivipera* venoms and *Macrovipera lebetina* ssp.
405 obtained by analytical C18 RP-HPLC. Chromatograms of *M. bornmuelleri*, *M.*
406 *bulgardaghica*, *M. xanthina*, *M. r. raddei*, *M. albizona* and *Macrovipera lebetina* ssp. (from
407 top to bottom). Venoms were applied to a C18 Vydac analytical column equilibrated with
408 5% solvent B in solvent A, and components were eluted using a segmented linear
409 gradient (blue line) going from 5 to 100% solvent B over a total run time of 40 min. The
410 run was performed at a flow rate of 1 mL/min and monitored at 214 nm. Shaded areas
411 reveal shared peaks between the studied venoms, and the red arrows indicate the unique
412 peaks in the venoms. Shaded areas highlight the shared peaks among *Montivipera*
413 venoms. Yellow: shared peaks at RT ~10.5 and 11.3 min, green: shared peak at RT ~15.7
414 min, red: shared peak at RT ~19 min


415

416 **3.4 Proteomics Analysis of *Montivipera* Venoms**

417 **3.4.1 Integration of Trypsin and MELD digestions in venom proteome analysis**

418 To evaluate the efficacy of integrating both Trypsin and MELD digestion protocols in the
419 analysis of *Montivipera* venoms, we compared the total number of proteins identified
420 using each digestion protocol separately and we used Venn diagrams to illustrate the
421 overlap. Our analysis revealed that MELD digestion identified between 45 and 84 unique
422 proteins that were not detected by Trypsin digestion alone (**Fig. 5**). On the other hand,
423 the Trypsin digestion led to the identification of 13 to 59 proteins that were not identified

424 by the MELD technique. This highlights the importance of combining both digestion
 425 protocols to get a more complete proteomic profile of the studied venoms.



426

427 **Fig. 5** Venn diagrams illustrating the number of proteins identified by the shotgun
 428 proteomics using each digestion protocol (Trypsin (blue) vs. MELD (grey)) and the
 429 overlap between both protocols

430

431 Using both digestion protocols, we identified between 129 and 179 proteins in the
 432 *Montivipera* venoms, all classified into 16 to 18 protein families. The complete list of
 433 identified proteins and peptides for the studied species is provided in **Supplementary**
 434 **Table S1**. On the other hand, the number of proteins found in the sister-genus
 435 *Macrovipera lebetina* ssp. was significantly lower, with 105 proteins grouped into 17
 436 families. **Table 1** summarizes the diversity of protein families and indicates the number

437 of isoforms detected within each family. For classification purposes, the TOP proteins,
 438 defined as those supported by the highest number of unique peptides within each group,
 439 were selected to represent the corresponding protein families.

440

441 **Table 1** Diversity and number of proteins and protein families identified in *Montivipera*
 442 venoms and *Macrovipera lebetina ssp.* using shotgun proteomics


	<i>M.</i> <i>bornmuelleri</i>	<i>M.</i> <i>bulgardaghica</i>	<i>M.</i> <i>xanthina</i>	<i>M.</i> <i>raddei</i>	<i>M.</i> <i>albizona</i>	<i>M.</i> <i>lebetina</i>
Nb. of proteins	129	174	145	179	167	105
Nb. of protein families	17	16	18	16	17	17
Id. protein families	Nb. of isoforms					
SVMP	36	36	23	32	40	18
PLA ₂	8	27	35	51	35	5
CTLs	24	27	33	22	37	33
SVSP	11	20	14	11	15	11
svVEGF	2	7	5	11	5	5
LAAO	3	3	3	3	3	5
Disintegrin	6	4	3	3	6	5
AP	1	3	1	1	1	9
NGF	5	1	3	3	3	3
KSPI	5	10	2	8	1	-
5'NT	1	1	1	1	1	1
PLB	1	1	1	1	1	1
CRiSP	4	-	11	9	8	1
SVMPi	-	-	1	-	2	1
NPs	2	1	1	-	-	1
GC	14	15	-	15	2	-
PDE	2	-	1	-	1	1
Hyaluronidase	-	1	4	5	-	1
Uncharacterized	4	17	3	3	6	4

443

444

445 **3.4.2 Diversity of enzymatic vs. non enzymatic venom components**

446 Our proteomics analysis revealed a higher diversity of enzymatic components compared
447 to non-enzymatic components for the five *Montivipera* venoms (**Fig. 6**). Notably, the
448 enzymatic components found in *Montivipera* venoms include PLA₂s, SVMPS, SVSPs,
449 LAAOs, APs, hyaluronidases, PLB, PDE, and 5'-NT. On the other hand, the identified
450 non-enzymatic components include families such as svVEGFs, CTLs, CRiSPs,
451 Disintegrins, NGF, NPs, KSPIs, and SVMIP inhibitors. *M. bornmuelleri* venom contains 53
452 enzymatic toxins and 40 non-enzymatic toxins. *M. bulgardaghica* and *M. albizona* venoms
453 shared similar numbers of enzymatic components (81 and 82, respectively), while fewer
454 non-enzymatic components were identified (53 and 56 isoforms, respectively). *M.*
455 *xanthina* venom contains 62 enzymatic components and 42 non-enzymatic components.
456 The enzymatic and non-enzymatic components of *M. raddei* were 75 and 45, respectively.
457 As a result, all *Montivipera* venoms exhibit a higher diversity of enzymatic toxins than their
458 non-enzymatic compounds. Interestingly, almost equal amounts of enzymatic and non-
459 enzymatic isoforms (49 and 43, respectively) were identified in the venom of *Macrovipera*
460 *lebetina* ssp.



461
 462 **Fig. 6** Bar chart showing the number of protein isoforms for enzymatic and non-enzymatic
 463 components in each of the *Montivipera* venoms and the *Macrovipera lebetina* ssp. venom

464
 465 **3.4.3 Protein families and their relative abundance in *Montivipera* venoms**

466 The proteomics analysis of *Montivipera* venoms indicated the presence of the
 467 predominant protein families described in the viperid venoms. Based on their relative
 468 abundance (**Fig. 7**), these protein families can be classified as major, secondary, and
 469 minor components. The major protein families constituting the *Montivipera* venoms were
 470 SVMPs, PLA₂s, SVSPs, svVEGFs, CTLs and Dis. *M. bornmuelleri* venom showed the
 471 highest SVMP abundance among all venoms, being the most abundant protein family in
 472 this venom, followed by svVEGFs, SVSPs, Dis, CTLs and PLA₂s. Alternatively, CTLs are
 473 the most abundant component in *M. bulgardaghica* venom, followed by SVSPs,

474 svVEGFs, PLA₂s, SVMPs and Dis. Notably, the major constituents of *M. xanthina* venom
475 were PLA₂s and svVEGFs followed by SVMPs, SVSPs, CTLs and Dis. Similarly, the most
476 abundant protein family in *M. r. raddei* venom is PLA₂, followed by CTLs, SVMPs, Dis,
477 svVEGFs and SVSPs. Regarding the *M. albizona* venom, its most abundant component
478 is the CTL family, followed by svVEGFs, SVMPs, PLA₂s, and SVSPs. The venom of the
479 closely related genus *Macrovipera lebetina* ssp. has PLA₂s and SVMPs as its major
480 components, followed by CTLs and Dis and SVSPs. The main difference observed in this
481 venom is its low abundance of svVEGFs (0.58%) as compared to the *Montivipera* venoms
482 (7.84 to 22.12%).

483 The secondary protein families constituting the *Montivipera* venoms include CRiSPs,
484 NGFs and LAAOs. Notably, CRiSPs were found only in the venoms of *M. albizona*, *M.*
485 *raddei* and *M. xanthina* at abundances of 7.69%, 6.32%, and 2.2%, respectively. The
486 abundances of NGFs and LAAOs in *M. bornmuelleri* venom are 2.44% and 2.02%,
487 respectively. *M. bulgardaghica*, *M. raddei*, *M. xanthina* and *M. albizona* exhibit lower
488 abundances of NGFs and LAAOs having less than 1% of each.


489 Various minor components are identified in the *Montivipera* venoms, having abundances
490 of less than 1% each. These components include 5'-NT, SVMP inhibitors, PDE, PLB,
491 KSPI, NPs, APs, glutamyl cyclase, and hyaluronidases. Altogether, these components
492 account for no more than 3.5% of the total venom compositions, and their presence is
493 inconsistent across species, being found in some venoms but absent in others.

494 Our results highlight a conserved venom composition across *Montivipera* species
495 characterized predominantly by high abundance of SVMPs, CTLs, PLA₂s, SVSPs,


496 svVEGFs and disintegrins. While the relative abundances of these toxin families varied
497 among species, they consistently represented the major components in all five
498 *Montivipera* venoms analyzed. Remarkably, all *Montivipera* venoms displayed a high
499 abundance of svVEGFs, highlighting a potential conserved role for these proteins within
500 the genus. In contrast, the venom of *Macrovipera lebetina* ssp. exhibited a markedly
501 different composition, characterized by lower levels of svVEGFs distinguishing it from the
502 *Montivipera* venoms. However, it should be noted that the present analysis was based on
503 relative quantification and, as such, comparisons between samples must be interpreted
504 with caution. Despite this limitation, the approach remains well suited to reveal consistent
505 trends in the distribution of toxin families across venoms [43]. Further refinement of
506 quantitative comparisons could be achieved by incorporating a defined protein mixture as
507 an internal reference standard. Alternatively, a more conventional but substantially more
508 labor-intensive strategy would involve quantification by RP-HPLC–MS, gel densitometry
509 and peptide-level quantification based on the Top 3 most intense ions obtained after
510 tryptic digestion [44,45].

511


512




M. bornmuelleri




M. bulgardaghica




M. xanthina



M. raddei



M. albizona



M. lebetinus



514 **Fig. 7** Pie charts showing the relative abundances of protein families in *Montivipera* and
515 *Macrovipera lebetina ssp.* venoms. Each section represents the relative abundance of a
516 single protein family within the venom (the values represented are percentages). “Others”
517 include the following minor protein families 5'-nucleotidase, SVMP inhibitor,
518 phosphodiesterase, phospholipase B, Kunitz-type serine protease inhibitors,
519 aminopeptidase, glutamyl cyclase, natriuretic peptide, and hyaluronidase.

520

521 **3.5 Comparative proteomics analysis of *Montivipera* venoms**

522 To evaluate the similarity between the five *Montivipera* venoms, we calculated the PSC
523 shown in **Table 2**. As we expected, the venom of the sister genus *Macrovipera lebetina*
524 *ssp.* shared the fewest proteins with the five *Montivipera* venoms investigated here (PSC
525 = 30.3 – 44.4). On the other hand, we estimated that the *Montivipera* species share
526 varying levels of similarity between their venom proteomes (PSC = 46.4 – 71.8). The
527 highest similarities were found between the venoms of *M. bulgardaghica* and *M. albizona*,
528 sharing 113 proteins (PSC = 66.3) and between the venoms of *M. xanthina* and *M.*
529 *albizona*, sharing 112 proteins (PSC = 71.8). The lowest estimated levels of similarity
530 were seen with the venom of *M. bornmuelleri*, which seems to have the least similar
531 venom to other *Montivipera* species.

532

533

534

535 **Table 2** Protein Similarity Coefficient (%) of the *Montivipera* venom proteomes and
 536 *Macrovipera lebetina* ssp.


	<i>M.</i> <i>bornmuelleri</i>	<i>M.</i> <i>bulgardaghica</i>	<i>M.</i> <i>raddei</i>	<i>M.</i> <i>albizona</i>	<i>M.</i> <i>xanthina</i>	<i>M.</i> <i>lebetina</i>
<i>M. bornmuelleri</i>	–	56.8	51.3	48.6	46.7	44.4
<i>M. bulgardaghica</i>	56.8	–	60.6	66.3	58.3	37.3
<i>M. r. raddei</i>	51.3	60.6	–	56.1	57.4	30.3
<i>M. albizona</i>	48.6	66.3	56.1	–	71.8	35.3
<i>M. xanthina</i>	46.7	58.3	57.4	71.8	–	36.8
<i>M. lebetina</i>	44.4	37.3	30.3	35.3	36.8	–

537 Values in bold and italics are repeated values for same species

538

539 To identify the common and unique protein isoforms among the five *Montivipera* venoms,
 540 we performed a Venn diagram analysis (**Fig. 8**). It revealed the presence of 39 common
 541 proteins across the five *Montivipera* venoms. These common proteins belonged to 11
 542 protein families (**Supplementary Table S2**). The common proteins among *Montivipera*
 543 venoms included 10 common SVMPs, identified based on sequence homology with
 544 SVMPs isolated from the venoms of *Macrovipera lebetinus* (1 isoform), *Vipera*
 545 *ammodytes* (4 isoforms), *Crotalus adamanteus* (3 isoforms), and *Echis carinatus* (2
 546 isoforms). We also identified 8 common CTLs among *Montivipera* venoms identified
 547 based on sequence homology with CTLs previously isolated from the venoms of
 548 *Macrovipera lebetina* (2 isoforms), *Vipera ammodytes* (3 isoforms), *Daboia siamensis* and
 549 *Daboia russelii* (1 isoform each). Additionally, 3 common PLA₂ isoforms were identified
 550 based on sequence match with two acidic PLA₂s from *Daboia russelii* and *Daboia*
 551 *siamensis* venoms and a basic PLA₂ from *Vipera berus* venom.

552



553

554 **Fig. 8:** Venn diagram illustrating the common and distinct proteins between the venoms
 555 of *Montivipera* species, including *M. bornmuelleri*, *M. bulgardaghica*, *M. xanthina*, *M. r.*
 556 *raddei* and *M. albizona*. The values represented are the number of identified proteins.

557

558 Discussion

559 In this study, we analyzed and compared the proteomic composition of five *Montivipera*
 560 species using trypsin and MELD digestion protocols followed by a shotgun proteomics
 561 approach. Accordingly, this work presents the first comprehensive proteomic
 562 characterization of the *M. bornmuelleri* venom and completes the previously published
 563 venom proteomes of *M. bulgardaghica*, *M. xanthina*, *M. raddei* and *M. albizona* [15,25–
 564 27]. We included in this study the analysis of the venom of *Macrovipera lebetina* ssp., the
 565 sister-genus of *Montivipera*, as an outgroup. This provides a broader phylogenetic
 566 perspective and allows the identification of lineage-specific venom traits. The evaluation

567 of these venoms using the same experimental approach allowed an accurate comparison
568 of their proteomic composition.

569 The venom composition of *Montivipera* species was characterized using a multi-
570 technique approach that included SDS-PAGE, RP-HPLC and shotgun MS. First, the
571 SDS-PAGE analysis demonstrated a rich protein profile within *Montivipera* venoms (13
572 to 19 distinct protein bands). This is higher than the number of bands typically reported
573 for other viperid genera, which generally range from 5 to 10 [46–48]. Consistently, RP-
574 HPLC chromatograms displayed numerous well-resolved peaks (23 – 33 peaks), further
575 reflecting the biochemical complexity of these venoms. The high number of
576 chromatographic peaks supports the presence of a wide array of peptides and proteins
577 in these venoms. This complexity was also confirmed by shotgun proteomics analysis,
578 which identified between 129 and 179 distinct proteins per venom sample. This is
579 significantly higher than what has been reported for other viperid genera analyzed by the
580 same technique, including species from *Vipera*, *Bothrops*, and *Deinagkistrodon* [48–50].
581 Similarly, the analyzed *Macrovipera lebetina* ssp. venom in this study exhibited a lower
582 number of identified venom components (105 components) as compared to *Montivipera*
583 venoms. Collectively, these methods revealed the complexity and high diversity of venom
584 components in *Montivipera* species. This result is in line with a previous comparative
585 proteomic study of various viperid genera, which identified *M. xanthina* venom as the most
586 diverse and complex among those evaluated, further supporting the exceptional
587 molecular diversity of *Montivipera* venoms [25]. This diversity is largely driven by the
588 presence of multiple protein isoforms resulting from evolutionary processes. These
589 isoforms are likely to enhance venom efficacy and versatility, as members of the same

590 protein family may exhibit variations in target specificity, binding affinity, or mechanism of
591 action [2].

592 Our investigation revealed that the *Montivipera* venoms are predominantly composed of
593 SVMPs, PLA₂s, SVSPs, svVEGFs, CTLs and Dis. These protein families are commonly
594 found in viperid venoms and contribute to their toxicity [1,51]. Their presence indicates
595 that *Montivipera* venoms can exhibit various clinical manifestations. First, SVMPs are key
596 contributors to the hemorrhagic activity of viperid venoms [52]. The presence of SVMPs
597 and their high abundance in all *Montivipera* venoms suggests a conserved hemorrhagic
598 potential across the genus, along with other biological functions attributed to SVMPs,
599 such as tissue degradation, interference with hemostasis, and modulation of inflammatory
600 processes. Among them, *M. bornmuelleri* venom exhibited the highest SVMP content,
601 consistent with clinical reports of local haemorrhage at the bite site in envenomed patients
602 [12]. This hemorrhagic effect was further demonstrated in zebrafish embryos, where the
603 venom induced visible pericardial bleeding [24]. Second, PLA₂s, another major
604 component of *Montivipera* venoms, are known to exhibit an array of biological activities
605 including neurotoxicity, cytotoxicity, myotoxicity, inflammation, and hemostatic alterations
606 [53]. All analyzed *Montivipera* venoms showed a high abundance of PLA₂s, with *M.*
607 *xanthina* and *M. raddei* venoms being particularly enriched in this toxin family. This
608 suggests that following envenomation by these species, more pronounced local and
609 systemic inflammatory or myotoxic symptoms might be observed. CTLs are known to
610 induce hemostatic alterations by interfering with platelet activity and vascular integrity.
611 These peptides can exert either procoagulant or anticoagulant effects, potentially
612 contributing to bleeding disorders or thrombotic events during envenomation [54,55].

613 Among the venoms analyzed, *M. bulgardaghica* and *M. albizona* exhibited the highest
614 CTL abundance, suggesting a greater capacity to disrupt coagulation homeostasis in
615 bites from these species. svVEGFs are known to increase vascular permeability and
616 promote angiogenesis, thereby facilitating the diffusion of other venom components
617 through tissues [56]. While svVEGFs are usually present in low abundance in viperid
618 venoms, all the analyzed *Montivipera* venoms displayed high abundance of this toxin
619 family. This enrichment appears to be a specific feature of the *Montivipera* lineage, as
620 evidenced by the low abundance of svVEGFs in the venom of *Macrovipera lebetinus ssp.*
621 Such a pattern may reflect an evolutionary adaptation of *Montivipera* venoms to facilitate
622 the dissemination of venom components.

623 It is important to note that the functional impact of toxin families could depend on factors
624 other than their abundance, such as the enzymatic activity, target specificity and
625 pharmacokinetic properties. In some cases, low abundance toxins could induce
626 significant biological activity or even engage in synergistic interactions and thus exhibit
627 strong biological outcomes upon envenomation [57]. Therefore, our abundance-based
628 interpretations provide useful hypotheses regarding the potential biological activities of
629 *Montivipera* venoms. However, they should be further confirmed by functional assays to
630 confirm the biological relevance of specific toxins in the context of venom action.

631 The main protein families identified in our study were like those reported by other research
632 groups. Previous proteomic studies on *Montivipera* venoms have reported
633 inconsistencies in the identified protein families across different studies, with each
634 capturing a partial venomomics profile of each species [15,25,27,42,58]. In our study, we
635 demonstrated the presence of all the protein families identified by previous studies

636 although with different abundances. In addition, we detected low-abundance proteins that
637 were not identified by other research groups, such as aminopeptidases, 5'-nucleotidase,
638 phospholipase B, aminopeptidases, glutamyl cyclase, Kunitz-type serine protease
639 inhibitors, natriuretic peptides, and hyaluronidases. Thus, the proteomic profiles identified
640 in this study aligned with and complemented the previously published venom proteomes
641 of four *Montivipera* species, including *M. bulgardaghica*, *M. xanthina*, *M. raddei* and *M.*
642 *albizona*. Importantly, this report provided the first characterization of *M. bornmuelleri*
643 venom which helped better understand the clinical manifestations induced upon
644 envenomation.

645 The discrepancies observed between venom proteomic studies, especially in low-
646 abundance components, could be attributed to two main reasons: venom intraspecific
647 variation and the choice of our proteomic approach. Venom composition can vary at the
648 species level based on geographic origin, diet, age, sex of the specimen and
649 environmental influences [59,60]. In our study, pooled venoms from vipers bred and kept
650 in captivity were used to minimize individual variability. Consequently, the resulting
651 proteomic profiles reflect venom composition under standardized conditions, in contrast
652 to studies based on wild-caught specimens, which often capture population-level and
653 ecologically driven variation. This could partly explain the variability in venom composition
654 revealed at the proteomic level. On the other hand, variability in results can arise from
655 factors related to the employed proteomic strategy, including sample preparation,
656 workflow, mass spectrometry parameters, and data analysis. In this study, we used the
657 shotgun proteomics approach, which was not previously used to analyze any of the
658 *Montivipera* venoms. Notably, the main advantage of the shotgun technique is that it does

659 not require a decomplexation step before mass spectrometric analysis, reducing the risk
660 of protein and peptide loss [28]. This technique proved to be effective for the analysis of
661 *Montivipera* venoms, as it enabled the detection of low-abundance proteins that were
662 missed by previously used techniques.

663 The similarity of *Montivipera* venom proteomes was evaluated using the protein similarity
664 coefficient (PSC). Our analysis revealed a high overall similarity in venom composition
665 across the studied species. The highest proteomic similarity was observed among *M.*
666 *bulgardaghica*, *M. albizona*, and *M. xanthina*. These three species are phylogenetically
667 classified within the *xanthina* complex (**Fig. 2**), which may account for their close venom
668 profiles [6]. Interestingly, although *M. bornmuelleri* also belongs to the *xanthina* complex,
669 its venom proteome exhibited the lowest similarity to the three previously mentioned
670 species. In contrast, *M. raddei*, a member of the phylogenetically distinct *raddei* complex,
671 showed a high PSC score with *M. bulgardaghica*, *M. xanthina*, and *M. albizona* venoms.
672 Notably, all four species with higher similarity (*M. bulgardaghica*, *M. xanthina*, *M.*
673 *albizona*, and *M. raddei*) have adjacent geographic ranges within Türkiye [6]. Conversely,
674 *M. bornmuelleri* is geographically isolated, being endemic to Lebanon [61]. These findings
675 suggest that environmental and ecological factors associated with geographic distribution
676 may exert a stronger influence on venom composition than phylogenetic relatedness
677 alone.

678 Furthermore, the Venn diagram analysis revealed a high number of shared proteins
679 between *Montivipera* venoms. The venoms that share most proteins were also shown to
680 be *M. bulgardaghica*, *M. albizona* and *M. xanthina*. This agrees with a previous proteomic
681 study showing high similarity between the venoms of *M. bulgardaghica*, *M. xanthina* and

682 *M. albizona* [27]. The Venn diagram revealed that most of the shared proteins among
683 *Montivipera* species belonged to the SVMs, CTLs, PLA₂s and SVSPs families. The latter
684 protein families are typically conserved in viperid venoms to ensure effective predation
685 and defense [1]. This suggests that envenomation by different *Montivipera* species may
686 produce comparable clinical manifestations. Furthermore, the presence of structurally
687 and functionally similar toxins implies a potential for cross-reactivity with the same
688 antivenom, particularly those targeting the common components responsible for the
689 pathophysiological effects during an envenomation. On the other hand, each venom
690 exhibited unique proteins that were not identified in other species, suggesting that the
691 *Montivipera* venoms have diverged enough to adapt their venom profiles to their specific
692 environments or prey. These results are consistent with the SDS-PAGE and RP-HPLC
693 profiles of *Montivipera* venoms, showing that they share a significant number of protein
694 bands and chromatographic peaks. However, each venom also displayed unique
695 differences, suggesting species-specific variations in composition.

696 This balance between conservation and diversity reflects how venom composition
697 evolves to suit ecological niches while retaining core functional elements typical of the
698 *Montivipera* genus. Variability in SV often arises as an adaptation to specific
699 environmental pressures and prey availability [2]. In the case of *Montivipera* species,
700 these snakes inhabit diverse and geographically distant regions, including the coastal
701 areas of Türkiye, the Anatolian and Armenian mountains, the Lebanese mountains, as
702 well as parts of Iran and Iraq (IUCN, <https://www.iucnredlist.org/>). Specifically,
703 *Montivipera* species are found at different elevations and therefore, they may encounter
704 different prey and experience diverse environmental pressures, which can drive venom

705 evolution to optimize their hunting and survival strategies. Additionally, evolutionary
706 adaptations allow these vipers to develop highly specialized venoms that are fine-tuned
707 to the ecological niche they occupy, targeting specific prey and ensuring efficient
708 predation in their respective environments.

709 It is important to note that the PSC provides only a minimal estimate of the similarity
710 between venom profiles. In the absence of transcriptomic data from the venom glands of
711 *Montivipera* species, protein identification was conducted through sequence homology
712 matching against the UniProt “Serpentes” database. The database lacks a
713 comprehensive inventory of venom proteins, particularly protein isoforms, that may
714 correspond to those present in *Montivipera* venoms. Thus, our analysis was based solely
715 on the identification of peptide fragments, without access to complete protein sequences.
716 Consequently, proteins considered identical may differ, highlighting the potential for
717 overestimation of true proteomic similarity. Accordingly, future studies integrating venom
718 gland transcriptomics, prey composition data, and appropriate multivariate statistical
719 frameworks will be necessary to rigorously evaluate hypotheses of ecological selection.

720

721 **Conclusion**

722 The proteomic characterization of five *Montivipera* species in this study highlighted the
723 exceptional diversity and complexity of their venoms. This report provides the first
724 publication of the *M. bornmuelleri* venom composition and allows us to validate and
725 complete the previously published venom proteomes of *M. bulgardaghica*, *M. albizona*,
726 *M. raddeji*, and *M. xanthina*. Most importantly, the analysis of these venoms with the same

727 proteomic approach allowed a reliable comparison of their composition. Our comparative
728 analysis revealed a high degree of similarity among *Montivipera* venoms, with certain
729 species exhibiting closer compositional profiles than others. In contrast, the venom of the
730 sister genus *Macrovipera lebetina* ssp. displayed the least similarity, underscoring its
731 phylogenetic distance and supporting its role as an appropriate outgroup in comparative
732 studies. Thus, this study provides a better understanding of the clinical manifestations
733 associated with *Montivipera* envenomation. Given the high degree of shared toxin families
734 and the limited availability of species-specific antivenoms, our findings shed light on the
735 potential use of existing antivenoms to treat envenomation by other *Montivipera* species,
736 offering valuable guidance in contexts where therapeutic options are scarce.

737

738

739

740 **Author Contributions:** CS, ZF, LQ, CM, CL: conceptualization; CS, DR, TC, LQ: formal
741 analysis; CS, DR, TC, VL: investigation, methodology; CS: writing original draft; AV, RF,
742 VL, ZF, LQ, CM, CL: review and editing; CM, CL, LQ: Supervision. All authors read,
743 agreed, and approved the final version of the manuscript.

744 **Funding:** This work was supported by the Eiffel Excellence program through a
745 scholarship (EIFFEL-DOCTORAT 2022 / n°P850081J) awarded to CS to fund her PhD
746 at the MITOVASC laboratory, University of Angers, France and by the Boehringer
747 Ingelheim fonds through a Travel grant awarded to CS to fund a one-month research stay
748 at the Mass spectrometry laboratory Liège-Belgium.

749 **Data availability:** All data generated or analyzed during this study are included in this
750 published article and its supplementary information files.

751

752 **Declarations**

753 **Ethics approval:** Not applicable.

754 **Consent to Publish:** Not applicable.

755 **Consent to Participate:** Not applicable.

Journal Pre-proof

756 **References:**

- 757 1. Oliveira, A.L.; Viegas, M.F.; Da Silva, S.L.; Soares, A.M.; Ramos, M.J.; Fernandes, P.A. The
758 Chemistry of Snake Venom and Its Medicinal Potential. *Nat Rev Chem* **2022**, *6*, 451–469,
759 doi:10.1038/s41570-022-00393-7.
- 760 2. Casewell, N.R.; Jackson, T.N.W.; Laustsen, A.H.; Sunagar, K. Causes and Consequences of
761 Snake Venom Variation. *Trends in Pharmacological Sciences* **2020**, *41*, 570–581,
762 doi:10.1016/j.tips.2020.05.006.
- 763 3. Gutiérrez, J.M.; Calvete, J.J.; Habib, A.G.; Harrison, R.A.; Williams, D.J.; Warrell, D.A.
764 Snakebite Envenoming. *Nat Rev Dis Primers* **2017**, *3*, 17079, doi:10.1038/nrdp.2017.79.
- 765 4. Frangieh, J.; Rima, M.; Fajloun, Z.; Henrion, D.; Sabatier, J.M.; Legros, C.; Mattei, C. Snake
766 Venom Components: Tools and Cures to Target Cardiovascular Diseases. *Molecules* **2021**, *26*,
767 doi:10.3390/molecules26082223.
- 768 5. Fry, B.G. From Genome to “Venome”: Molecular Origin and Evolution of the Snake Venom
769 Proteome Inferred from Phylogenetic Analysis of Toxin Sequences and Related Body
770 Proteins. *Genome Res.* **2005**, *15*, 403–420, doi:10.1101/gr.3228405.
- 771 6. Stümpel, N.; Rajabizadeh, M.; Avci, A.; Wüster, W.; Joger, U. Phylogeny and Diversification of
772 Mountain Vipers (Montivipera, Nilson et al., 2001) Triggered by Multiple Plio–Pleistocene
773 Refugia and High-Mountain Topography in the Near and Middle East. *Molecular*
774 *Phylogenetics and Evolution* **2016**, *101*, 336–351, doi:10.1016/j.ympev.2016.04.025.
- 775 7. Makran, B.; Fahmi, L.; Pla, D.; Sanz, L.; Oukkache, N.; Lkhider, M.; Ghalim, N.; Calvete, J.J.
776 Snake Venomics of Macrovipera Mauritanica from Morocco, and Assessment of the Para-
777 Specific Immunoreactivity of an Experimental Monospecific and a Commercial Antivenoms.
778 *Journal of Proteomics* **2012**, *75*, 2431–2441, doi:10.1016/j.jprot.2012.02.022.
- 779 8. Schulte, L.; Damm, M.; Avella, I.; Uhrig, L.; Erkoc, P.; Schiffmann, S.; Fürst, R.; Timm, T.;
780 Lochnit, G.; Vilcinskas, A.; et al. Venomics of the Milos Viper (Macrovipera Schweizeri)
781 Unveils Patterns of Venom Composition and Exochemistry across Blunt-Nosed Viper
782 Venoms. *Front. Mol. Biosci.* **2023**, *10*, 1254058, doi:10.3389/fmolb.2023.1254058.
- 783 9. Avella, I.; Damm, M.; Di Nicola, M.R.; Dresler, J.; İğci, N.; Kariş, M.; Kazemi, S.M.; Kreuels, B.;
784 Paolino, G.; Sarigiannis, Y.; et al. The Biology and Toxinology of Blunt-Nosed Vipers. *npj*
785 *biodivers* **2025**, *4*, 21, doi:10.1038/s44185-025-00090-w.
- 786 10. Anil, A.B.; Anil, M.; Kara, O.D.; Bal, A.; Özhan, B.; Aksu, N. Mannitol Therapy in Three Cases
787 with Severe Edema Due to Snakebite: Case Report. *Turkiye Klinikleri J Med Sci* **2011**, *31*,
788 720–723, doi:10.5336/medsci.2009-13354.
- 789 11. Al-Musawi, M.; Chanbour, H.; El Masri, J.; Awad, R.; Armash, K. Erectile Dysfunction and
790 Permanent Bladder Areflexia Following Montivipera Bornmuelleri Snakebite. *Cureus* **2021**,
791 doi:10.7759/cureus.17968.
- 792 12. Tabbara, F.; Abdul-Nabi, S.; sADEK, R.; Kazzi, Z.; El Zahran, T. A Case Report of a Lebanon
793 Viper (Montivipera Bornmuelleri) Envenomation in a Child. *Clinical Practice and Cases in*
794 *Emergency Medicine* **2022**, *6*, 319–323, doi:10.5811/cpcem.2022.2.56176.
- 795 13. Hassanian-Moghaddam, H.; Monzavi, S.M.; Shirazi, F.M.; Warrell, D.A.; Mehrpour, O. First
796 Report of a Confirmed Case of Montivipera Latifii (Latifi’s Viper) Envenoming and a
797 Literature Review of Envenoming by Montivipera Species. *Toxicon* **2022**, *207*, 48–51,
798 doi:10.1016/j.toxicon.2021.12.020.

- 799 14. Lamb, T.; De Haro, L.; Lonati, D.; Brvar, M.; Eddleston, M. Antivenom for European *Vipera*
800 Species Envenoming. *Clinical Toxicology* **2017**, *55*, 557–568,
801 doi:10.1080/15563650.2017.1300261.
- 802 15. Nalbantsoy, A.; Hempel, B.-F.; Petras, D.; Heiss, P.; Göçmen, B.; İçci, N.; Yildiz, M.Z.;
803 Süßmuth, R.D. Combined Venom Profiling and Cytotoxicity Screening of the Radde's
804 Mountain Viper (*Montivipera Raddei*) and Mount Bulgar Viper (*Montivipera Bulgardaghica*)
805 with Potent Cytotoxicity against Human A549 Lung Carcinoma Cells. *Toxicon* **2017**, *135*, 71–
806 83, doi:10.1016/j.toxicon.2017.06.008.
- 807 16. Yalcın, H.T.; Ozen, M.O.; Gocmen, B.; Nalbantsoy, A. Effect of Ottoman Viper (*Montivipera*
808 *Xanthina* (Gray, 1849)) Venom on Various Cancer Cells and on Microorganisms.
809 *Cytotechnology* **2014**, *66*, 87–94, doi:10.1007/s10616-013-9540-z.
- 810 17. Nalbantsoy, A.; Erel, Ş.B.; Köksal, Ç.; Göçmen, B.; Yildiz, M.Z.; Karabay Yavaşoğlu, N.Ü. Viper
811 Venom Induced Inflammation with *Montivipera Xanthina* (Gray, 1849) and the Anti-Snake
812 Venom Activities of *Artemisia Absinthium* L. in Rat. *Toxicon* **2013**, *65*, 34–40,
813 doi:10.1016/j.toxicon.2012.12.017.
- 814 18. Accary, C.; Hraoui-Bloquet, S.; Hamze, M.; Mallem, Y.; El Omar, F.; Sabatier, J.-M.; Desfontis,
815 J.-C.; Fajloun, Z. Protein Content Analysis and Antimicrobial Activity of the Crude Venom of
816 *Montivipera Bornmuelleri*; a Viper from Lebanon. *Infect Disord Drug Targets* **2014**, *14*, 49–
817 55, doi:10.2174/1871526514666140522114754.
- 818 19. Accary, C.; Rima, M.; Kouzahya, A.; Hleihel, W.; Sadek, R.; Desfontis, J.C.; Fajloun, Z.; Hraoui-
819 Bloquet, S. Effect of the *Montivipera Bornmuelleri* Snake Venom on Human Blood:
820 Coagulation Disorders and Hemolytic Activities. *Open J Hematol* **2014**, *5*, 1,
821 doi:10.13055/ojhmt_5_1_4.140609.
- 822 20. Accary, C.; Hraoui-Bloquet, S.; Sadek, R.; Alameddine, A.; Fajloun, Z.; Desfontis, J.-C.;
823 Mallem, Y. The Relaxant Effect of the *Montivipera Bornmuelleri* Snake Venom on Vascular
824 Contractility. *J Venom Res* **2016**, *7*, 10–15.
- 825 21. Yacoub, T.; Rima, M.; Sadek, R.; Hleihel, W.; Fajloun, Z.; Karam, M. *Montivipera Bornmuelleri*
826 Venom Has Immunomodulatory Effects Mainly Up-Regulating pro-Inflammatory Cytokines
827 in the Spleens of Mice. *Toxicology Reports* **2018**, *5*, 318–323,
828 doi:10.1016/j.toxrep.2018.02.011.
- 829 22. Sawan, S.; Yaacoub, T.; Hraoui-Bloquet, S.; Sadek, R.; Hleihel, W.; Fajloun, Z.; Karam, M.
830 *Montivipera Bornmuelleri* Venom Selectively Exhibits High Cytotoxic Effects on
831 Keratinocytes Cancer Cell Lines. *Experimental and Toxicologic Pathology* **2017**, *69*, 173–178,
832 doi:10.1016/j.etp.2017.01.001.
- 833 23. Haddoub, C.; Rima, M.; Heurtebise, S.; Lawand, M.; Jundi, D.; Sadek, R.; Amigorena, S.;
834 Fajloun, Z.; Karam, M.C. Cytotoxic Effect of *Montivipera Bornmuelleri*'s Venom on Cancer
835 Cell Lines: In Vitro and in Vivo Studies. *PeerJ* **2020**, *8*, e9909, doi:10.7717/peerj.9909.
- 836 24. Sahyoun, C.; Krezel, W.; Mattei, C.; Sabatier, J.-M.; Legros, C.; Fajloun, Z.; Rima, M. Neuro-
837 and Cardiovascular Activities of *Montivipera Bornmuelleri* Snake Venom. *Biology (Basel)*
838 **2022**, *11*, 888, doi:10.3390/biology11060888.
- 839 25. Abu Aisheh, M.; Kayili, H.M.; Numanoglu Cevik, Y.; Kanat, M.A.; Salih, B. Composition
840 Characterization of Various Viperidae Snake Venoms Using MS-Based Proteomics N-
841 Glycoproteomics and N-Glycomics. *Toxicon* **2023**, *235*, 107328,
842 doi:10.1016/j.toxicon.2023.107328.

- 843 26. Jafari, Z.; Bandehpour, M.; Kaboli, M.; Kazemi, B. Partial Proteomics Analysis of Montivipera
844 Raddei Venom: Partial Proteomics of Montivipera Raddei Venom. *Trends in Peptide and*
845 *Protein Sciences* **2023**, *8*, 1-5 (e2), doi:10.22037/tpps.v8i1.41610.
- 846 27. Damm, M.; Karış, M.; Petras, D.; Nalbantsoy, A.; Göçmen, B.; Süßmuth, R.D. Venomics and
847 Peptidomics of Palearctic Vipers: A Clade-Wide Analysis of Seven Taxa of the Genera *Vipera* ,
848 *Montivipera* , *Macrovipera* , and *Daboia* across Türkiye. *J. Proteome Res.* **2024**, *23*, 3524–
849 3541, doi:10.1021/acs.jproteome.4c00171.
- 850 28. Sahyoun, C.; Rima, M.; Mattei, C.; Sabatier, J.-M.; Fajloun, Z.; Legros, C. Separation and
851 Analytical Techniques Used in Snake Venomics: A Review Article. *Processes* **2022**, *10*, 1380,
852 doi:10.3390/pr10071380.
- 853 29. Lomonte, B.; Calvete, J.J. Strategies in “snake Venomics” Aiming at an Integrative View of
854 Compositional, Functional, and Immunological Characteristics of Venoms. *J Venom Anim*
855 *Toxins Incl Trop Dis* **2017**, *23*, 26, doi:10.1186/s40409-017-0117-8.
- 856 30. Morsa, D.; Baiwir, D.; La Rocca, R.; Zimmerman, T.A.; Hanozin, E.; Grifnée, E.; Longuespée,
857 R.; Meuwis, M.-A.; Smargiasso, N.; Pauw, E.D.; et al. Multi-Enzymatic Limited Digestion: The
858 Next-Generation Sequencing for Proteomics? *J. Proteome Res.* **2019**, *18*, 2501–2513,
859 doi:10.1021/acs.jproteome.9b00044.
- 860 31. Amorim, F.G.; Redureau, D.; Crasset, T.; Freuville, L.; Baiwir, D.; Mazzucchelli, G.; Menzies,
861 S.K.; Casewell, N.R.; Quinton, L. Next-Generation Sequencing for Venomics: Application of
862 Multi-Enzymatic Limited Digestion for Inventorying the Snake Venom Arsenal. *Toxins* **2023**,
863 *15*, 357, doi:10.3390/toxins15060357.
- 864 32. Redureau, D.; Amorim, F.G.; Crasset, T.; Berger, I.; Schaffitzel, C.; Menzies, S.K.; Casewell,
865 N.R.; Quinton, L. Dual Proteomics Strategies to Dissect and Quantify the Components of
866 Nine Medically Important African Snake Venoms. *Toxins* **2025**, *17*, 243,
867 doi:10.3390/toxins17050243.
- 868 33. Laemmli, U.K. Cleavage of Structural Proteins during the Assembly of the Head of
869 Bacteriophage T4. *Nature* **1970**, *227*, 680–685, doi:10.1038/227680a0.
- 870 34. Perez-Riverol, Y.; Bandla, C.; Kundu, D.J.; Kamatchinathan, S.; Bai, J.; Hewapathirana, S.;
871 John, N.S.; Prakash, A.; Walzer, M.; Wang, S.; et al. The PRIDE Database at 20 Years: 2025
872 Update. *Nucleic Acids Res* **2025**, *53*, D543–D553, doi:10.1093/nar/gkae1011.
- 873 35. Calvete, J.J.; Escolano, J.; Sanz, L. Snake Venomics of *Bitis* Species Reveals Large Intragenus
874 Venom Toxin Composition Variation: Application to Taxonomy of Congeneric Taxa. *J.*
875 *Proteome Res.* **2007**, *6*, 2732–2745, doi:10.1021/pr0701714.
- 876 36. Lenk, P.; Kalyabina, S.; Wink, M.; Joger, U. Evolutionary Relationships among the True Vipers
877 (Reptilia: Viperidae) Inferred from Mitochondrial DNA Sequences. *Molecular Phylogenetics*
878 *and Evolution* **2001**, *19*, 94–104, doi:10.1006/mpev.2001.0912.
- 879 37. Behrooz, R.; Kaboli, M.; Arnal, V.; Nazarizadeh, M.; Asadi, A.; Salmanian, A.; Ahmadi, M.;
880 Montgelard, C. Conservation Below the Species Level: Suitable Evolutionarily Significant
881 Units among Mountain Vipers (the Montivipera Raddei Complex) in Iran. *Journal of Heredity*
882 **2018**, *109*, 416–425, doi:10.1093/jhered/esy005.
- 883 38. Nei, M.; Kumar, S. *Molecular Evolution and Phylogenetics*; Oxford University Press New York,
884 NY, 2000; ISBN 978-0-19-513584-8.

- 885 39. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular Evolutionary Genetics
886 Analysis across Computing Platforms. *Molecular Biology and Evolution* **2018**, *35*, 1547–1549,
887 doi:10.1093/molbev/msy096.
- 888 40. Guindon, S.; Dufayard, J.-F.; Lefort, V.; Anisimova, M.; Hordijk, W.; Gascuel, O. New
889 Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the
890 Performance of PhyML 3.0. *Systematic Biology* **2010**, *59*, 307–321,
891 doi:10.1093/sysbio/syq010.
- 892 41. Huelsenbeck, J.P.; Ronquist, F. MRBAYES: Bayesian Inference of Phylogenetic Trees.
893 *Bioinformatics* **2001**, *17*, 754–755, doi:10.1093/bioinformatics/17.8.754.
- 894 42. Sanz, L.; Ayvazyan, N.; Calvete, J.J. Snake Venomics of the Armenian Mountain Vipers
895 *Macrovipera Lebetina Obtusa* and *Vipera Raddei*. *Journal of Proteomics* **2008**, *71*, 198–209,
896 doi:10.1016/j.jprot.2008.05.003.
- 897 43. Krey, J.F.; Wilmarth, P.A.; Shin, J.-B.; Klimek, J.; Sherman, N.E.; Jeffery, E.D.; Choi, D.; David,
898 L.L.; Barr-Gillespie, P.G. Accurate Label-Free Protein Quantitation with High- and Low-
899 Resolution Mass Spectrometers. *J. Proteome Res.* **2014**, *13*, 1034–1044,
900 doi:10.1021/pr401017h.
- 901 44. Lomonte, B.; Escolano, J.; Fernández, J.; Sanz, L.; Angulo, Y.; Gutiérrez, J.M.; Calvete, J.J.
902 Snake Venomics and Antivenomics of the Arboreal Neotropical Pitvipers *Bothriechis*
903 *Lateralis* and *Bothriechis Schlegelii*. *J. Proteome Res.* **2008**, *7*, 2445–2457,
904 doi:10.1021/pr8000139.
- 905 45. Fusco, L.S.; Beraldo-Neto, E.; Calvete, J.J.; Sanz, L.; Lanari, L.C.; Lorente, C.; Leiva, L.C.;
906 Pimenta, D.; De Roodt, A.R.; Pla, D. Venomic and F(Ab')₂ Antivenomic Studies of *Bothrops*
907 *Alternatus* Venom Proteins. *International Journal of Biological Macromolecules* **2025**, *318*,
908 144777, doi:10.1016/j.ijbiomac.2025.144777.
- 909 46. Lang Balija, M.; Leonardi, A.; Brgles, M.; Sviben, D.; Kurtović, T.; Halassy, B.; Križaj, I.
910 Biological Activities and Proteomic Profile of the Venom of *Vipera Ursinii* Ssp., a Very Rare
911 Karst Viper from Croatia. *Toxins* **2020**, *12*, 187, doi:10.3390/toxins12030187.
- 912 47. Kumkate, S.; Chanhom, L.; Thiangtrongjit, T.; Noiphrom, J.; Laoungboa, P.; Khow, O.;
913 Vasaruchapong, T.; Sitprijia, S.; Chaiyabutr, N.; Reamtong, O. Venomics and Cellular Toxicity
914 of Thai Pit Vipers (*Trimeresurus Macrops* and *T. Hageni*). *Toxins (Basel)* **01 16**, *12*,
915 doi:10.3390/toxins12010054.
- 916 48. Jiménez-Charris, E.; Montoya-Gómez, A.; Torres, J.K.; Gómez-Díaz, M.; Bolívar-García, W.
917 First Functional and Proteomic Analysis of *Bothrops Asper* Snake Venom from Gorgona
918 Island - Colombia, and Its Comparative Characterization with Two Colombian Southwest
919 Ecoregions. *Biochimie* **2022**, *194*, 19–27, doi:10.1016/j.biochi.2021.12.005.
- 920 49. Gopcevic, K.; Karadzic, I.; Izrael-Zivkovic, L.; Medic, A.; Isakovic, A.; Popović, M.; Kekic, D.;
921 Stanojkovic, T.; Hozic, A.; Cindric, M. Study of the Venom Proteome of *Vipera Ammodytes*
922 *Ammodytes* (Linnaeus, 1758): A Qualitative Overview, Biochemical and Biological Profiling.
923 *Comp Biochem Physiol Part D Genomics Proteomics* **3 AD**, *37*, 100776,
924 doi:10.1016/j.cbd.2020.100776.
- 925 50. Nie, X.; He, Q.; Zhou, B.; Huang, D.; Chen, J.; Chen, Q.; Yang, S.; Yu, X. Exploring the Five-
926 Paced Viper (*Deinagkistrodon Acutus*) Venom Proteome by Integrating a Combinatorial
927 Peptide Ligand Library Approach with Shotgun LC-MS/MS. *Journal of Venomous Animals and*
928 *Toxins including Tropical Diseases* **2021**, *27*.

- 929 51. Damm, M.; Hempel, B.-F.; Süßmuth, R.D. Old World Vipers-A Review about Snake Venom
930 Proteomics of Viperinae and Their Variations. *Toxins (Basel)* **2021**, *13*, 427,
931 doi:10.3390/toxins13060427.
- 932 52. Baldo, C.; Jamora, C.; Yamanouye, N.; Zorn, T.M.; Moura-da-Silva, A.M. Mechanisms of
933 Vascular Damage by Hemorrhagic Snake Venom Metalloproteinases: Tissue Distribution and
934 In Situ Hydrolysis. *PLoS Negl Trop Dis* **2010**, *4*, e727, doi:10.1371/journal.pntd.0000727.
- 935 53. Sampat, G.H.; Hiremath, K.; Dodakallanavar, J.; Patil, V.S.; Harish, D.R.; Biradar, P.;
936 Mahadevamurthy, R.K.; Barvaliya, M.; Roy, S. Unraveling Snake Venom Phospholipase A2: An
937 Overview of Its Structure, Pharmacology, and Inhibitors. *Pharmacol. Rep* **2023**, *75*, 1454–
938 1473, doi:10.1007/s43440-023-00543-8.
- 939 54. Pereira, D.F.D.C.; Matias Ribeiro, M.S.; de Sousa Simamoto, B.B.; Dias, E.H.V.; Costa, J.O.;
940 Santos-Filho, N.A.; Bordon, K.C.F.; Arantes, E.C.; Dantas, N.O.; Silva, A.C.A.; et al. Baltetin: A
941 New C-Type Lectin-like Isolated from Bothrops Alternatus Snake Venom Which Act as a
942 Platelet Aggregation Inhibiting. *J Chromatogr B Analyt Technol Biomed Life Sci* **2021**, *1173*,
943 122695, doi:10.1016/j.jchromb.2021.122695.
- 944 55. Castanheira, L.E.; Lopes, D.S.; Gimenes, S.N.C.; Deconte, S.R.; Ferreira, B.A.; Alves, P.T.; Filho,
945 L.R.G.; Tomiosso, T.C.; Rodrigues, R.S.; Yoneyama, K.A.G.; et al. Angiogenenic Effects of
946 BpLec, a C-Type Lectin Isolated from Bothrops Pauloensis Snake Venom. *International*
947 *Journal of Biological Macromolecules* **2017**, *102*, 153–161,
948 doi:10.1016/j.ijbiomac.2017.04.012.
- 949 56. Ferreira, I.G.; Pucca, M.B.; Oliveira, I.S.D.; Cerni, F.A.; Jacob, B.D.C.D.S.; Arantes, E.C. Snake
950 Venom Vascular Endothelial Growth Factors (svVEGFs): Unravelling Their Molecular
951 Structure, Functions, and Research Potential. *Cytokine & Growth Factor Reviews* **2021**, *60*,
952 133–143, doi:10.1016/j.cytogfr.2021.05.003.
- 953 57. Deshwal, A.; Phan, P.; Datta, J.; Kannan, R.; Thallapuranam, S.K. A Meta-Analysis of the
954 Protein Components in Rattlesnake Venom. *Toxins (Basel)* **2021**, *13*, 372,
955 doi:10.3390/toxins13060372.
- 956 58. Igci N; Petras D; Goçmen B; Süßmuth R; Yildiz M Z; Ozel-Demiralp FD İgci N, Petras D,
957 Göçmen B, Süßmuth R, Yıldız MZ, Özel-Demiralp FD. Comparative Venomic Characterization
958 of Four Medicinally Important Turkish Vipers (Macrovipera Lebetina, Montivipera Xanthina,
959 Vipera Ammodytes, V. Kaznakovi).; Berlin, Germany, March 22 2025; p. 3.
- 960 59. Montealegre-Sánchez, L.; Montoya-Gómez, A.; Jiménez-Charris, E. Individual Variations in
961 the Protein Profiles and Functional Activities of the Eyelash Palm Pit-Viper (Bothriechis
962 Schlegelii) Venom from the Colombian Southwest Region. *Acta Tropica* **2021**, *223*, 106113,
963 doi:10.1016/j.actatropica.2021.106113.
- 964 60. He, Y.; Gao, J.; Lin, L.; Ma, X.; Ji, X. Age-Related Variation in Snake Venom: Evidence from
965 Two Snakes (Naja Atra and Deinagkistrodon Acutus) in Southeastern China. *AHR* **2014**, *5*,
966 119–127, doi:10.3724/SP.J.1245.2014.00119.
- 967 61. Souad Hraoui-bloquet; Riyad Sadek; Claudine Accary; Walid Hleihel; Ziad Fajloun AN
968 ECOLOGICAL STUDY OF THE LEBANON MOUNTAIN VIPER MONTIVIPERA BORNMUELLERI
969 (WERNER, 1898) WITH A PRELIMINARY BIOCHEMICAL CHARACTERIZATION OF ITS VENOM.
970 *Lebanese Science Journal* **2011**, *13*.
- 971

Highlights

- Proteomic profiling of five *Montivipera* venoms using shotgun proteomics revealed extensive toxin diversity.
- Major toxin families were conserved, while their relative abundances varied across species.
- Comparative analysis revealed 39 conserved proteins across *Montivipera* venoms, highlighting strong interspecific similarity.
- Discovery of low-abundance toxin families expands current knowledge of *Montivipera* venom diversity.

Journal Pre-proof

Ethical approval and consent to participate

Not applicable.

Journal Pre-proof

Declaration of competing interest

The authors declare that they have no competing financial interests.

Journal Pre-proof